Publications by authors named "Joji Kuramoto"
Background/aim: The treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) typically involves surgery, irradiation, and chemotherapy (single or combination therapy). However, the impact of these therapies on the survival of patients with NSCLC with multiple extrathoracic metastases has not yet been determined. Therefore, in the present study, we examined the prognostic effect of multimodal treatment for brain metastases in patients with NSCLC with multiple extrathoracic metastases in the absence of driver mutations.
View Article and Find Full Text PDFArticle Synopsis
- Immune-checkpoint inhibitors (ICIs) are used for treating non-small cell lung cancer (NSCLC), with programmed death-ligand 1 expression as a common but insufficient predictor of their effectiveness.
- This study evaluated tumor growth rate, specifically the initial rapidity of tumor progression (IRP), as a simpler predictor of ICI treatment response among NSCLC patients treated with drugs like nivolumab, pembrolizumab, or atezolizumab.
- Results showed a negative correlation between IRP and time to treatment failure, indicating that faster initial tumor growth is linked to poorer therapeutic outcomes with ICIs.
Background: In the eighth edition of the TNM classification of lung cancer, the M1b and M1c descriptors are newly defined by the number of extrathoracic metastases. To verify the prognostic value of these descriptors in Japan, we reclassified our cases and re-evaluated prognosis in M1b and M1c patients.
Methods: All non-small cell lung cancer (NSCLC) patients with extrathoracic metastases who visited Saitama Medical Center from 2010 to 2016 were evaluated, divided according to the eighth edition of the TNM classification criteria into two groups (M1b, patients with single extrathoracic metastasis, and M1c, patients with multiple extrathoracic metastases), and followed up until December 31, 2017.